Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
OXURION : Information on the Total Number of Voting Rights (Denominator)…
Atlas Special Opportunities, LLC has converted 3 convertible bonds in Oxurion resulting in a EUR 75,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – July 8 2026 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major…
Actusnews Wire
08/07/2026
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer)…
Atlas Special Opportunities, LLC heeft 3 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 75.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1. Leuven, BELGIUM– 8 juli 2026 – 18u00 CET – Overeenkomstig artikel 15 van de Wet van 2 mei 2007 op de…
Actusnews Wire
08/07/2026
Oxurion achieves another milestone in the expansion of the Exagis platform with…
Leuven, BELGIUM – July 6th, 2026 – 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announced the commercial launch of the Exagis electronic Trial Master File (eTMF) module, achieving another key milestone in the execution of its strategy to build a comprehensive modular eClinical software platform…
Actusnews Wire
06/07/2026
Oxurion bereikt een nieuwe mijlpaal in de uitbouw van het Exagis-platform met de…
Leuven, BELGIË – 6 juli 2026 – 18u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf gevestigd in Leuven, kondigt aan de commerciële lancering van de Exagis electronic Trial Master File (eTMF)-module, waarmee opnieuw een belangrijke mijlpaal wordt bereikt in de uitvoering van haar strategie om een volledig modulair eClinical-softwareplatform te bouwen…
Actusnews Wire
06/07/2026
DMS GROUP : HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT ON JUNE 30, 2026
July 2, 2026 – 8.45 am – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, communicates the half-year results of the liquidity contract entrusted by DMS Group to Natixis Oddo BHF dated May 7, 2025…
Actusnews Wire
02/07/2026
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…
Leuven, BELGIË – 26 juni 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparantiekennisgeving op 25 juni 2026 van Atlas…
Actusnews Wire
26/06/2026
Oxurion Receives Transparency Notification from Atlas Special Opportunities II…
Leuven, BELGIUM – June 26, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 25, 2026, from Atlas Special Opportunities II, LLC…
Actusnews Wire
26/06/2026
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…
Leuven, BELGIË – 24 juni 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparantiekennisgeving op 23 juni 2026 van Atlas…
Actusnews Wire
24/06/2026
Oxurion Receives Transparency Notification from Atlas Special Opportunities II…
Leuven, BELGIUM – June 24, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 23, 2026, from Atlas Special Opportunities II, LLC…
Actusnews Wire
24/06/2026
THX Pharma Announces the Appointment of Sophie Jacq Lapointe to its Board of…
A recognized leader in the pharmaceutical and biotechnology industry joins the Board of Directors to support THX Pharma's next phase of growth and development. Lyon, France – June 23, 2026 – 6:00 p.m. CEST – THX Pharma (Theranexus), an innovative biopharmaceutical company focused on the treatment of rare neurological diseases, today announced the…
Actusnews Wire
23/06/2026
DMS GROUP STRENGTHENS ITS GOVERNANCE: APPOINTMENT OF BPIFRANCE INVESTISSEMENT AS…
DMS GROUP STRENGTHENS ITS GOVERNANCE: APPOINTMENT OF BPIFRANCE INVESTISSEMENT AS A BOARD DIRECTOR Vladislav TCACI, CFA, Investment Director in the Direct Investment department (Large Cap) of Bpifrance, representative of Bpifrance Investissement appointed as a director on the Board of Directorsof DMS Group June 22, 2026 – 8:45 a.m…
Actusnews Wire
22/06/2026
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II…
Leuven, BELGIË – 18 juni 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparantiekennisgeving op 17 juni 2026 van Atlas…
Actusnews Wire
19/06/2026
Oxurion Receives Transparency Notification from Atlas Special Opportunities II…
Leuven, BELGIUM – June 18, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 17, 2026, from Atlas Special Opportunities II, LLC…
Actusnews Wire
19/06/2026
THX PHARMA : Allinvest Securities Initiates Analyst Coverage on THX Pharma with…
Lyon, France – June 16, 2026 – 8:00 AM CEST – THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces the initiation of analyst coverage by Allinvest Securities. In a research report titled "THX Pharma: Transformed profile, reconfigured risk/reward", Allinvest…
Actusnews Wire
16/06/2026
OXURION : Belangrijke marktvalidatie: Laboratoires Pierre Fabre gebruiken het…
Leuven, BELGIË – 15 juni 2026 – 19u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf gevestigd in Leuven, kondigt aan dat Laboratoires Pierre Fabre Exagis gebruikt, zijn eigen platform voor het beheer van klinische data ontwikkeld binnen zijn dochteronderneming Axiodis CRO. Dit gebruik vormt een nieuwe validatie van de…
Actusnews Wire
15/06/2026
OXURION : Major market validation: Pierre Fabre Laboratories uses Oxurion's…
Leuven, BELGIUM – June 8, 2026 – 19:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announces that Pierre Fabre Laboratories is utilizing Exagis, its proprietary clinical data management platform developed by its subsidiary, Axiodis CRO. This ongoing use represents a significant commercial…
Actusnews Wire
15/06/2026
KLEA HOLDING : Klea Pharmaceuticals launch its business with a strong partner
Paris, 11 June 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group specialising in the acquisition, development and digitalisation of companies across various sectors, announces the launch of its new subsidiary, Klea Pharmaceuticals, which will market a portfolio of licensed medicines in high-growth markets across the Middle East and Africa…
Actusnews Wire
11/06/2026
Oxurion Receives Transparency Notification from Atlas Special Opportunities II…
Leuven, BELGIUM – June 10, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 9, 2026, from Atlas Special Opportunities II, LLC…
Actusnews Wire
10/06/2026
DMS GROUP OBTAINS MARKETING AUTHORIZATION FOR ITS NEW ONYX RADIOLOGY MOBILE
DMS GROUP OBTAINS MARKETING AUTHORIZATION FOR ITS NEW ONYX RADIOLOGY MOBILE Obtaining certification under the European Medical Device Regulation (MDR) Commercial launch of ONYX, a new generation of ultra-mobile and intelligent radiology mobile First deliveries expected in Q3 2026 DMS Group strengthens its position in the global mobile radiology…
Actusnews Wire
10/06/2026
THX Pharma (Theranexus) and Exeltis secure EMA approval of the paediatric…
Approval of the PIP by the EMA's Paediatric Committee (PDCO) clears a critical regulatory gate, paving the way for a Paediatric Use Marketing Authorisation (PUMA) submission and securing up to 10 years of European market protection for TX01 in Niemann-Pick type C disease Lyon, France – Madrid, Spain – June 9, 2026 – 6:00 pm CEST – THX Pharma…
Actusnews Wire
09/06/2026
THERANEXUS : THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand…
The three partners are proud to jointly serve as Platinum Sponsors of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program and the upcoming initiation of their international pivotal Phase 3 study Lyon, France – Gentilly, France – Austin, Texas, United States – June 9, 2026 – 8:00 am CEST – On the…
Actusnews Wire
09/06/2026
Oxurion launches a software-driven growth strategy with Exagis
Key Highlights Under Oxurion's ownership, Exagis has evolved from an internal eCRF solution into a broader Clinical Data Management System (CDMS) serving external customers Exagis has already supported more than 25 clinical projects involving over 16,000 patients, 600 clinical sites and 18 sponsors The platform is now commercializing, separately…
Actusnews Wire
08/06/2026
Oxurion lanceert een softwaregedreven groeistrategie met Exagis
Belangrijkste hoogtepunten Onder de vleugels van Oxurion is Exagis gegroeid van een interne eCRF-oplossing naar een breder Clinical Data Management System (CDMS) voor externe klanten Exagis heeft al meer dan 25 klinische projecten ondersteund met meer dan 16.000 patiënten, 600 klinische sites en 18 sponsors Het platform wordt nu apart…
Actusnews Wire
08/06/2026
Oxurion Announces Results on the Annual Shareholders' Meeting of 1 June 2026
Leuven, BELGIUM – June 3, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, held its annual shareholders' meeting on June 1, 2026. The shareholders approved all items on the agenda of the annual shareholders' meeting. All documents pertaining to the annual shareholders' meeting held on June 1…
Actusnews Wire
03/06/2026
Altri Comunicati
